Mylan receives FDA approval for generic version of organ transplant drug Prograf

Mylan receives FDA OK for generic Prograf version

CANONSBURG, Pa. — The drugmaker Mylan Inc. said Tuesday it received Food and Drug Administration approval for a generic version of the Astellas Pharma drug Prograf, which is used to prevent rejection of transplanted organs.

Mylan received approval for 0.5-, 1- and 5-milligram versions of the drug, which has the generic name of tacrolimus capsules. It will launch the drug immediately.

Prograf is used to suppress the immune system and prevent the rejection of transplanted livers, kidneys, and hearts. In July, Watson Pharmaceuticals Inc. also received approval to sell a generic version of the drug.